Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89zr-oxine-ry_sw01
- Development stage
- Phase 2
- Lead developer
- Jiangsu Renocell Biotech
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
89zr-oxine-ry_sw01 is a radiolabeled mesenchymal stem cell therapy in development for the treatment of systemic sclerosis, lupus nephritis, and type 2 diabetes mellitus with established diabetic nephropathy. The product consists of mesenchymal stem cells labeled with zirconium-89 oxine ([^89Zr]oxinate4), enabling both therapeutic action and in vivo tracking via positron emission tomography (PET) imaging. The labeling allows monitoring of cell distribution and persistence after administration. The primary mechanism is believed to be immunomodulation and anti-fibrotic activity by the administered stem cells, while the ^89Zr label provides a means for non-invasive imaging to study biodistribution and kinetics. Developed by Jiangsu Renocell Biotech (also referred to as Jiangsu Ruiyuan Biotechnology), this therapy is currently being evaluated in early-phase clinical trials for systemic sclerosis and other immune-mediated diseases[1][2][3].
- Other names
- 89Zr-Oxine-RY_SW01RY_SW01
Beyond the preview
Go deeper on 89zr-oxine-ry_sw01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89zr-oxine-ry_sw01.